Home > Pressrelease > Transdermal Drug Delivery System Market size to exceed $61Bn by 2032

Transdermal Drug Delivery System Market size to exceed $61Bn by 2032

  • Published Date: April 28, 2023

Transdermal Drug Delivery System Market size is projected to surpass USD 61 billion by 2032, as per a new research report announced by Global Market Insights Inc.

A commendable rise in the adoption of transdermal patches among patients for pain-free administration of drugs will favor market growth by 2032. An increasing number of patients opting for self-administration of drugs at home will further escalate market progress. This apart, the introduction of novel drug delivery systems in the market by renowned and new players will create a favorable development outlook for the transdermal drug delivery system industry over the forecast period.

Transdermal semisolids to become popular due to their proven efficacy and safety

Transdermal drug delivery system market share from the transdermal semisolids segment is expected to grow over 7.5% CAGR by 2032. Semisolids are further divided into gels, ointment, and spray. Transdermal drug delivery systems offer several benefits, including reduced inter-patient variability of drug doses, improved efficacy, and enhanced safety, among others, which have favored their adoption in recent years and may continue doing so in the coming years as well.

Browse key industry insights spread across 195 pages with 319 market data tables & 15 figures & charts from the report “Transdermal Drug Delivery Systems Market Size By Type (Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches}, Transdermal Semisolids {Gels, Ointments, Sprays}) By Application (Pain Management, Hormonal Applications, Central Nervous System Disorders, Cardiovascular Diseases) By End-use (Hospitals, Clinics, Homecare Settings), COVID-19 Impact Analysis, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032” in detail along with the table of contents:

Mounting burden of brain-related diseases to drive product adoption in central nervous system disorders applications

Transdermal drug delivery system market from the central nervous system disorders application segment is set to depict 8.5% CAGR by 2032. The transdermal drug delivery system is an effective alternative to the conventional method of using drugs for central nervous system diseases. The development of transdermal-based nutraceuticals will offer the benefit of improved solubility, enhanced bioavailability, and targeted administration of drugs in brain-related diseases, among others, which will help propel segment gains through 2032.

Consistent technological expansions to drive product demand across clinics

Transdermal drug delivery system revenue from the clinics segment crossed over USD 4 billion in 2022. Growing emphasis on the adoption of transdermal drug delivery systems across clinical settings will accelerate market progress. Moreover, the integration of cutting-edge technologies, such as mechanical arrays or microneedle arrays, will enhance market performance.

Flourishing healthcare sector to bolster industry progression across Europe

Europe transdermal drug delivery system market is likely to hit USD 16 billion by 2032. Increasing R&D spending by key market players to innovate and launch new products is expected to spur product demand across the region. Furthermore, the presence of developed healthcare infrastructure in Europe and enhanced health awareness will accelerate market expansion.

Escalating drug approvals to strengthen the competitive landscape

Notable players in the transdermal drug delivery system industry are Novartis, Mylan, Amneal Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., UCB, Hisamitsu Pharmaceutical Co., Inc., Corium, Inc., Micropoint Technologies, Sparsha Pharma International Pvt. Ltd., and Luye Pharma.


Authors: Rupali Swain, Subodh Kharad